Further to your conjecture on 1.5 v 2 mg studies. My understanding is effect size is close in aggregate BUT 2 mg is better for primary end points on pain and function. Read SW comments on confidence in achieving strong data set to allow PAR to monetise before read out. SW has chosen his words carefully and NOT given away too much here
Further to your conjecture on 1.5 v 2 mg studies. My...
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
-0.010(4.08%) |
Mkt cap ! $82.20M | |||
| Open | High | Low | Value | Volume |
| 26.0¢ | 26.0¢ | 23.0¢ | $317.0K | 1.319M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 49998 | 23.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 16000 | 2 |
View Market Depth
| Last trade - 16.10pm 06/05/2024 (20 minute delay) ? |
|
|||||
|
Last
23.5¢ |
Change
-0.010 ( 6.00 %) |
||||
| Open | High | Low | Volume | ||
| 25.0¢ | 26.0¢ | 23.0¢ | 531376 | ||
| Last updated 15.58pm 06/05/2024 ? | |||||
| PAR (ASX) Chart |